Literature DB >> 1832295

Induction of long-term but reversible unresponsiveness after activation of murine T cell hybridomas.

F Andris1, M Van Mechelen, N Legrand, P M Dubois, M Kaufman, J Urbain, O Leo.   

Abstract

T cell receptor (TCR)-mediated stimulation of murine T cell hybridomas induces cell activation and lymphokine production. We have observed that following productive activation, T cell hybridomas become refractory to a subsequent stimulation. Hyporesponsiveness is long-lasting but reversible, and is not due to reduced receptor expression. It is noteworthy that hyporesponsiveness is cell autonomous, persists in spite of cell division and does not require continuous exposure to ligands. Hyporesponsive cells retain the ability to produce lymphokines in response to pharmacological agents bypassing receptor triggering, indicating that they possess a functional enzymatic machinery for interleukin 2 synthesis and secretion. Reduced phosphatidylinositol hydrolysis was observed in these cells in response to TCR stimulation, suggesting that hyporesponsiveness result from defective transduction of activation signals. The development of unresponsiveness following receptor stimulation resembles desensitization, and may thus play an important role in the regulation of an immune response and in the induction of immune tolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832295     DOI: 10.1093/intimm/3.6.609

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

Review 1.  Immunological self/nonself discrimination: integration of self vs nonself during cognate T cell interactions with antigen-presenting cells.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness.

Authors:  J P Abastado; Y C Lone; A Casrouge; G Boulot; P Kourilsky
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.